

**LABEL IN PART:** (Bag) "Delaware Complete Chick Starter Medicated For the prevention of Coccidiosis in Chicken \* \* \* Active Drug Ingredient: Sulfaquinoxaline 0.015% \* \* \* Ingredients \* \* \* Manufactured by Delaware Milling Company, Inc. Deposit, New York."

**RESULTS OF INVESTIGATION:** Analysis showed that the article contained approximately 183 percent of the declared amount of sulfaquinoxaline.

**LIBELED:** 10-2-61, Dist. Maine.

**CHARGE:** 501(c)—when shipped, the strength of the article differed from that which it was purported to possess; and 502(a)—the label statement "Sulfaquinoxaline 0.015%" was false and misleading as applied to this article which contained more than the declared amount of sulfaquinoxaline.

**DISPOSITION:** 11-1-61. Default—delivered to a public institution, to be mixed with an equal amount of nonmedicated chick starter, for animal consumption.

## DRUGS AND DEVICES ACTIONABLE BECAUSE OF FALSE AND MISLEADING CLAIMS

### DRUGS FOR HUMAN USE\*

**6761. Powdered chirata and Bhaji tablets.** (F.D.C. No. 45062. S. No. 25-731 R.)

**QUANTITY:** 38 bags, each containing 93 to 116 lbs. of chirata, and 14 145-lb. bags of chirata; 1,704 120-tablet btls. and 116 240-tablet btls. of *Bhaji tablets*, at Glendale, Calif., in possession of New Era Tea Co.

**SHIPPED:** (Chirata only), between 12-10-57 and 4-22-59, from India.

**LABEL IN PART:** (Btl.) "Temple Bell East Indian Herbal Bhaji Tablets Bhaji Tablets Contain The Valuable Plant Chirata In Combination With Rose Petals and Maté \* \* \* New Era Tea Company, 1736 Victory Boulevard, Glendale, California."

**ACCOMPANYING LABELING:** Pamphlets entitled "Temple Bells East Indian Bhaji Tablets."

**RESULTS OF INVESTIGATION:** The dealer commissioned the tableting of the mixture of chirata, rose petals, and maté in Los Angeles, Calif., from whence the tablets were returned to the dealer at Glendale, Calif.

**LIBELED:** 10-26-60, S. Dist. Calif.

**CHARGE:** 502(a)—while held for sale, the labeling of the articles contained false and misleading representations that the articles were adequate and effective as a treatment for purifying blood, bladder, gall bladder, liver, and kidney troubles, low blood pressure, high blood pressure, enlarged heart, conditions of the bronchial tubes, nerve disorders, nerve stabilizer, skin conditions, anemia, tiredness, habitual constipation, debility of convalescence, intermittent fevers, swelling of the hands, arthritis, pimples, irritability, insomnia, mental conditions, menopausal psychosis, menopausal syndrome, and that it would produce good health, extend physical endurance, and restore pep and energy.

**DISPOSITION:** On 2-17-61, a claim and answer were filed by the dealer, but were withdrawn on 12-13-61. On 1-22-62, a default decree ordering destruction was entered.

**6762. Mavene wafers.** (F.D.C. No. 46335. S. No. 98-350 R.)

**QUANTITY:** 448 cases, each containing 6 boxes, each box containing 12 5-unit vials, at Kansas City, Mo.

\*See also Nos. 6743, 6745-6747, 6751-6755, 6757, 6758.

**SHIPPED:** Between 5-8-61 and 7-6-61, from New York, N.Y., by Yorktown Products Corp.

**LABEL IN PART:** (Vial) "5 Mavene Wafers \* \* \* Contains Magnesium Carbonate, Calcium Carbonate, Dehydrated Milk and Cream, Beef Protein\*, Milk Casein, Cocoa, Coconut Oil, Sucrose, Ethyl Vanillin, Malt Extract \* \* \* Manufactured for Yorktown Products Corp., New York, N.Y."

**ACCOMPANYING LABELING:** Booklet entitled "Medical Facts About Excess Acidity."

**LIBELED:** 9-15-61, W. Dist. Mo.

**CHARGE:** 502(a)—when shipped, the labeling of the article contained false and misleading representations that the article was adequate and effective for the treatment and prevention of stomach and duodenal ulcers.

**DISPOSITION:** 11-1-61. Consent—claimed by the shipper and released for relabeling.

**6763. Lecitabs (lecithin tablets).** (F.D.C. No. 46437. S. No. 70-975 R.)

**QUANTITY:** 8 cases, each containing 12 90-tablet btl., 1 case, containing 10 90-tablet btl., 8 cases, each containing 12 180-tablet btl., and 3 cases, each containing 12 540-tablet btl., at Minneapolis, Minn.

**SHIPPED:** Between 8-27-58 and 7-21-60, from Chicago, Ill., by National Lecithin, Inc.

**LABEL IN PART:** (Btl.) "National Lecitabs Lecithin Tablets A Natural Food Product Highly concentrated extra rich, Soya Lecithin formula of 95% oil-free Phosphatides. Ingredients: Soya Lecithin, in a base of nonfat, dry milk solids and soy protein. Natural flavoring added. Sole Distributors: National Lecithin, Inc. Chicago 26, Ill."

**LIBELED:** 9-11-61, Dist. Minn.; amended libel 9-15-61.

**CHARGE:** 502(a)—when shipped, the label of the article bore false and misleading representations that the article was adequate and effective to promote utilization of fat and to lower blood cholesterol.

The libel alleged also that the article was misbranded under the provisions of the law applicable to foods, as reported in notices of judgment on foods.

**DISPOSITION:** 10-31-61. Default—destruction.

**6764. All-In-One capsules.** (F.D.C. No. 44558. S. No. 28-918 R.)

**QUANTITY:** 5 cases of 72 80-capsule ctns. and 3 cases of 36 160-capsule ctns. at St. Paul, Minn.

**SHIPPED:** 2-2-60, from West Hempstead, N.Y., by John H. Mathis, Inc.

**LABEL IN PART:** (Ctn.) "All-In-One Capsules A dietary Supplement \* \* \* Each capsule contains \* \* \* Packed for and Distributed by State Pharmacal Co., Chicago 1, Ill."

**ACCOMPANYING LABELING:** Leaflet entitled "The Story of All-In-One Capsules."

**LIBELED:** 5-2-60, Dist. Minn.

**CHARGE:** 502(a)—when shipped, the labeling of the article contained false and misleading representations that the article was an adequate and effective treatment for obesity and controlling the appetite, and that the article would give the feeling of a full, contented stomach when reducing, and would keep its consumer feeling fine while losing weight.